- Company
- SK Bioscience loses MSD vaccines but nabs GSK vaccines?
- by Kim, Jin-Gu Jan 6, 2021 06:19am
- SK Bioscience is reportedly sealing the deal on commercializing four types of GSK vaccines in South Korea. When the deal is finalized, SK Bioscience would be able to fill the gap of four types of MSD vaccinea taken over by HK inno.N last year. According to a pharmaceutical industry source on Jan. 5, SK Bioscience and GSK Korea are i
- Policy
- The vaccination date of AZ’s vaccine will be advanced
- by Lee, Jeong-Hwan Jan 6, 2021 06:19am
- The MFDS announced that it will accelerate the marketing approval period as much as possible by approval/review process of AstraZeneca's COVID-19 vaccine, which was accepted for approval on the 4th, and the national lot release at same time. The approval/review system takes up to 40 days and lot release takes up to 20 days, but it is techn
- Policy
- Prostate cancer treatment Erleada by Janssen was approved
- by Lee, Tak-Sun Jan 6, 2021 06:19am
- Janssen Korea has received domestic approval for a new prostate cancer drug. The emergence of new options after Zytiga (Abiraterone acetate) is expected to expand its influence in the prostate cancer treatment market. The MFDS approved Janssen's Erleada (Apalutamide) in Korea on the 30th. It is approved as a combination therapy with andro
- Company
- Patient copayment on Dupixent drops from 60% to 10%
- by Jan 6, 2021 06:18am
- From the break of the new year, the copayment burden on the patients prescribed with an atopic dermatitis treatment Dupixent would be reduced significantly. Sanofi Aventis Korea’s Dupixent would be applied with a special case reimbursement from Jan. 1, 2021 for the patients with severe case of atopic dermatitis. Accordingly, their copay
- Policy
- AZ has applied for domestic approval of COVID-19 vaccine
- by Lee, Tak-Sun Jan 5, 2021 05:18pm
- The MFDS announced today (4th) that AstraZeneca Korea's application for item approval for COVID-19 vaccine (code name: AZD1222) has been received. This vaccine is a 'viral vector vaccine' manufactured by putting COVID-19 surface antigen gene into a chimpanzee adenovirus vector. Viral vector vaccines are manufactured by inserting viral ant
- Policy
- Generics for Arcoxia are coming soon
- by Lee, Tak-Sun Jan 4, 2021 05:58am
- Generic for Arcoxia, COX-2 anti-inflammatory analgesic is expected to be released soon. As the PMS ended on the 22nd of last month, it was confirmed that the generic company received the application on the 23rd, the next day. Since generic companies have already confirmed patent avoidance, they are expected to market their products as so
- Policy
- Contract for 20 million people with Moderna was completed
- by Lee, Jeong-Hwan Jan 4, 2021 05:55am
- The government officially announced today (31) that it has signed a contract to purchase 20 million COVID-19 vaccines with Moderna, a US pharmaceutical company. As a result, Korea has secured the quantity of Moderna vaccines before the end of this year. This amount exceeds 100% of the population of Korea, and it is evaluated that it is su
- Policy
- GBP510 by SK Bioscience has been clinically approved
- by Lee, Tak-Sun Jan 4, 2021 05:55am
- Another COVID-19 vaccine developed by SK Bioscience has been approved for clinical trials in Korea. The MFDS announced on the 31st that it has approved the clinical trial of the domestically developed COVID-19 vaccine GBP510. GBP510 is a vaccine candidate being developed by SK Bioscience and is different from NBP2001, which was clinically approv
- Company
- Industry busy with M&A and investment for new opportunity
- by Chon, Seung-Hyun Dec 31, 2020 06:21am
- In the year 2020, many of South Korean pharmaceutical companies turned their eyes on new potential businesses. They reported major M&A news more than before. Some of them also took a bold step into bio company investment to find new opportunities. ◆GC and Celltrion ink notable M&A deals in hopes of finding new lucrative businesses
- Policy
- Review of new evaluation index for innovative certification
- by Lee, Jeong-Hwan Dec 31, 2020 06:20am
- When the MOHW is certified as an Innovative Pharmaceutical Company, it is expected to initiate a reorganization of the system to create new evaluation indicators that take into account the characteristics of overseas pharmaceutical companies. The goal is to establish a pharmaceutical and bio environment that provides a basis for domestic i
